Liquid-Phase Degarelix Synthesis Scalability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for large-scale industrial synthesis of the decapeptide Degarelix face challenges such as limited capacity, excessive reagents, and difficulties in removing impurities like racemization and side-chain protection, making them unsuitable for high-volume production.
Innovation Solution
A liquid-phase synthesis process involving specific peptide coupling reagents, organic solvents, and cleaving agents is developed to efficiently couple and deprotect Degarelix intermediates, reducing racemization and impurity issues, and allowing for scalable production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If Boc-solid phase peptide synthesis (SPPS) methodology is used, then Degarelix can be synthesized with sufficient quantities, but the method requires HF cleavage and is not suited to large scale industrial synthesis
Solution Approach 1:
The patent changes the synthesis parameters from solid-phase to liquid-phase methodology, replacing HF cleavage with milder cleavage agents like TFA, and enabling scalable industrial production while maintaining sufficient quantity output
Solution Approach 2:
The patent substitutes the mechanical solid-phase synthesis system with a liquid-phase system, replacing the resin-based solid support mechanism with solution-phase chemistry that allows for easier scaling and different cleavage mechanisms
2Quantity of substance
If classical peptide solution synthesis (liquid phase peptide synthesis) is used, then larger quantities of product can be produced, but expense attributable to the large excess of coupling reagents, additives, and amino acids is increased
Solution Approach 1:
The patent optimizes the liquid-phase synthesis parameters by using optimized coupling reagents (HATU, HBTU, TBTU) and conditions that reduce the excess reagent requirements while maintaining high yields, thereby reducing material loss and expense
3Quantity of substance
If liquid phase peptide synthesis is used, then larger quantities of product can be produced, but difficulties in removing impurities like racemization and side-chain protection arise
Solution Approach 1:
The patent applies preliminary protective group strategies and optimized coupling sequences that prevent racemization and side-chain protection issues before they occur, rather than attempting to remove impurities after synthesis
Solution Approach 2:
The patent uses optimized coupling reagents and conditions (HATU, HBTU, TBTU with specific bases and solvents) that minimize racemization and improve purity, along with optimized purification protocols
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves high yields and purity of Degarelix with minimal racemization and impurities, enabling larger-scale production while maintaining the quality of the peptide.
Implementation Method 1
coupling (P4)Ac-AA1-AA4 with (Pε)AA5-AA10NH2 in an organic solvent comprising the two peptides, a peptide coupling reagent and an organic amine base dissolved therein
Implementation Method 2
cleaving the protecting group Pε from a Degarelix precursor according to formula (P4)(Pε)Ac-AA1-AA10NH2 in an organic solvent comprising the precursor and a cleaving agent dissolved therein
Data Source
Figure 1
Figure 2
Figure 2
AI summary
The present invention relates to a liquid (or solution)-phase manufacturing process for preparing the decapeptide Degareiix, its amino-protected precursor, and other useful intermediates. The invention further relates to polypeptides useful in the solution-phase manufacturing process and to the purification of Degareiix itself. The manufacturing process comprises the step of cleaving the e-amino protecting group ?e from a Degareiix precursor according to formula {P4)(Pe)Ac-AA1-AA10-NH2 in an organic solvent comprising the precursor and a cleaving agent dissolved therein: wherein P4 is a hydroxyl-protecting group or hydrogen, preferably hydrogen.